HighTower Advisors LLC Increases Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

HighTower Advisors LLC lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,683 shares of the medical instruments supplier’s stock after acquiring an additional 212 shares during the quarter. HighTower Advisors LLC’s holdings in LeMaitre Vascular were worth $524,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of LMAT. Allspring Global Investments Holdings LLC grew its position in shares of LeMaitre Vascular by 48.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock valued at $1,227,000 after acquiring an additional 4,330 shares during the period. Barclays PLC lifted its stake in LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Compass Planning Associates Inc bought a new position in LeMaitre Vascular during the fourth quarter valued at $567,000. Charles Schwab Investment Management Inc. grew its holdings in LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after purchasing an additional 11,395 shares during the period. Finally, Congress Asset Management Co. raised its stake in shares of LeMaitre Vascular by 1.8% in the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock valued at $66,555,000 after buying an additional 13,009 shares during the period. 84.64% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 10.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target for the company. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Trading Down 1.0 %

Shares of NASDAQ:LMAT opened at $83.05 on Monday. The company has a 50 day moving average of $93.07 and a 200 day moving average of $94.42. The stock has a market cap of $1.87 billion, a P/E ratio of 45.38, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were issued a $0.20 dividend. The ex-dividend date was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.96%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.